chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 28.0
Sex: F
Vaccine: HPV4
Symptoms: Injury
Clinical narrative: Information has been received regarding a case in litigation concerning a female (age unreported) who was vaccinated with a dose of GARDASIL vaccine (yeast). Subsequently the patient experienced a "serious personal injury." Additional information has been requested.  12/24/09 MR and DC summary for DOS 09/13/09-09/17/09. DX: Probable conversion reaction with R shoulder twitching and migraine.  Pt c/o R arm twitching, shoulder twitching, and loss of consciousness.  Pt reported R upper arm weakness that did not resolve with physical and occupational therapy. Pt responded to stimuli and stable postictal. Neuro examination: normal. Tx: Dilantin and Kapra. Dr did not think Pt had a true epileptiform process. Pt suggested to have neurologist and psychiatrist follow ups. Pt discharged home.
Age: 18.0
Sex: F
Vaccine: HPV4
Symptoms: Syncope
Clinical narrative: Information has been received from a laboratory assistant concerning an 18 year old female patient who on 26-MAR-2008 was vaccinated with a first dose of GARDASIL vaccine (yeast) (lot #659964/1978U) and on 26-MAR-2008 she received her second dose of GARDASIL vaccine (yeast) (lot # 660393/0067X). Concomitant therapy included meningococcal ACYW conj vaccine (dip toxoid). The reporter reported that the patient fainted briefly after receiving the first dose of GARDASIL vaccine (yeast). She recovered from the fainting on the same day. She did not faint after the second injection. Additional information has been requested.
Sex: F
Vaccine: HPV4
Symptoms: Head injury, Loss of consciousness
Clinical narrative: Information has been received from a physician concerning a female (age unreported) who was vaccinated with a dose of GARDASIL vaccine, lot number not reported. Within five minutes the patient passed out for an extended period of time, hit her head on the wall and went to the emergency room. This is one of 2 cases from the same source. Additional information has been requested.
Age: 20.0
Sex: F
Vaccine: HPV4
Symptoms: Antiphospholipid syndrome, Arthralgia, Hepatic enzyme increased, Liver function test
Clinical narrative: Information has been received from a nurse practitioner concerning a 20 year old female with no pertinent medical history and no allergies who on 26-DEC-2007 was vaccinated with the first dose of GARDASIL vaccine (lot# 655327/1287U) 0.5mL IM. On 10-MAR-2008, the patient was vaccinated with the second dose of GARASIL vaccine (lot# 0151X) 0.5mL IM. Concomitant therapy included minocycline (manufacturer unknown). The patient was on minocycline for about a year and this was recently discontinued because of the liver test: In June 2008, the patient had elevated liver enzymes. The patient had no symptoms but the liver function test was done because patient was worried family history of diseases. The patient sought medical attention. Additional information has been requested.  10/08/08 This is in follow-up to report(s) previously submitted on 7/15/2008. Initial and follow-up information has been received from a nurse practitioner concerning a 21 year old female with family history of antiphospholipid antibody syndrome and no allergies who on 26-DEC-2007 was vaccinated with the first dose of GARDASIL (lot# 655327/1287U) 0.5ml IM in the left deltoid. On 10-MAR-2008, the patient was vaccinated with the second dose of GARDASIL (lot# 0151X) 0.5ml IM in the right deltoid. On 27-JUN-2008 the patient was vaccinated with the third dose of GARDASIL (lot# 0250X) IM in the left deltoid. Concomitant therapy included minocycline. It was reported that the patient was seen in the office on 27-JUN-2008 for her third dose of HPV vaccine and the patient stated she had had joint pain for 3 months. In June 2008 she was taken to a rheumatologist who drew liver enzymes and "they were elevated". The patient had no symptoms but the liver function test was done because patient was worried family history of diseases. The patient was on minocycline for about a year and this was recently discontinued because of the liver test. The patient stated her levels were returning to normal, and subsequently, she was vaccinated with her third dose. There was no illness at time of vaccination. The outcome of the patient's arthralgia was unknown. Additional information has been requested.
Age: 14.0
Sex: F
Vaccine: HPV4
Symptoms: Mastitis, Ultrasound scan abnormal
Clinical narrative: Information has been received from a physician concerning a 14 year old female with drug hypersensitivity to PANCOF and with no known pertinent medical history who on 23-APR-2008 was vaccinated with a first and only dose of GARDASIL vaccine IM (lot# 654272/0073X). Concomitant therapy included MENACTRA. The patient developed mastitis after receiving GARDASIL vaccine. A sonogram was performed. The patient was treated with an antibiotic (unspecified). The patient was recovering. The patient sought medical attention by seeing the physician. Additional information has been requested.
Age: 26.0
Sex: F
Vaccine: HPV4
Symptoms: Pruritus, Urticaria
Clinical narrative: Information has been received from a licensed practical nurse concerning a 26 year old female with no known pertinent medical history or drug reactions/allergies who on 23-JUN-2008 was vaccinated with a first dose of GARDASIL vaccine (yeast) 0.5 ml IM in her arm. There was no concomitant medication. Later on 23-JUN-2008 the patient began to experience itching which developed into hives that night. No lab or diagnostic studies were performed. The patient took oral diphenhydramine hydrochloride (BENADRYL). The patient called the office on 25-JUN-2008 to report this reaction. Additional information has been requested.  This is in follow-up to report(s) previously submitted on 7/15/2008. Information has been received from a licensed practical nurse concerning a 26 year old female with no known pertinent medical history or drug reaction or drug reactions/allergies who at 3:30 pm on 23-JUN-2008 was vaccinated with a first dose of GARDASIL 0.5 ml IM in her right deltoid. There was no concomitant medication. The patient began itching 20 minutes (also reported as two hours) after the injection. At 3:30 pm on 23-JUN-2008, 2 to 3 hours past the injection, the patient developed hives in her arms and neck. On 25-JUN-2008 the patient called the office and stated that she still had hives. The patient was self treating with oral BENADRYL and cortisone. Additional information has been requested.
Age: 18.0
Sex: F
Vaccine: HPV4
Symptoms: Anxiety, Panic attack, Syncope
Clinical narrative: Information has been received from a consumer concerning her approximately 19 year old daughter with no known drug allergies and a history of infectious meningitis during infancy and epilepsy (seizure-free for eight years) who on 22-APR-2008 was vaccinated with the first dose of GARDASIL vaccine (yeast). There was no concomitant medication. On approximately 22-APR-2008 the patient fainted after administration of her first dose. On approximately 24-APR-2008, "two days later", the patient experienced "panic attack" followed by two weeks of generalized anxiety. On 08-MAY-2008 patient was recovered. The patient sought unspecified medical attention via telephone. No further information is available.
Age: 18.0
Sex: F
Vaccine: HPV4
Symptoms: Rash, Rash pustular
Clinical narrative: Information has been received from a physician concerning an approximately 19 year old female with no known allergies and a history of folliculitis due to Razor who on 24-JUN-2008 was vaccinated with the third dose of GARDASIL vaccine (lot no. 660391/0063X). There was no concomitant medication. On approximately 26-JUN-008, "approximately two days later," the patient developed raised spots on her forearms and legs. The patient was treated with oral BENADRYL and she was recovering from the symptom. Additional information has been requested. This is in follow-up to report (s) previoulsy submitted on 7/15/2008. Information has been received from a physician concerning an approximately 19 year old femaled with no known allergies and a history of folliculitis due to RAZOR who on 24-JUN-2008 was vaccinated with the third dose GARDARSIL vaccine (lot no. 660191/0063X). There was no concomitant  medication. On approximately 26-JUN-2006, "approximately two day later", the patient developed raised spots on her forearms and legs. The patient was treated with oral BENADRYL and she was recovering fromthe symptom. Follow-up information was received from the physician stating that the physician could not recall which patient this was. Additional information is not expected.
Age: 17.0
Sex: F
Vaccine: HPV4
Symptoms: Cervical dysplasia, Smear cervix abnormal
Clinical narrative: Information has been received from a nurse practitioner (N.P.) concerning an approximately 19 year old female with no known drug allergies who on 09-DEC-2006 was vaccinated intramuscularly with the first 0.5 ml dose of GARDASIL vaccine (yeast) (lot no. 653938/0954F). On 03-MAR-2007 the patient was vaccinated intramuscularly with the second 0.5 ml dose of GARDASIL vaccine (yeast) (lot no. 655503/0012U). On 06-JUL-2007 the patient was vaccinated intramuscularly with the third 0.5 ml dose of GARDASIL vaccine (yeast) (lot no. 658094/0524U). The patient claimed that she was not sexually active prior to the completion of the GARDASIL vaccine (yeast) series. On an unspecified date the patient tested positive for "low grade squamous intraepithelial lesion for SIN 1". The patient was recovering from the symptoms. The patient was seen by the nurse practitioner to seek unspecified medical attention. Additional information has been requested.  This is in follow-up to report (s) previously submitted on 7/15/2008. Follow up information was received from a physician. It was reported that the patient received the first dose of GARDASIL vaccine in the right upper deltoid and received second and third dose in the left upper deltoid. The patient was on birth control (unspecified). The patient was diagnosed with low grade squamous intraepithelial lesion (low-grade LSIL). Additional information has been requested.
Age: 20.0
Sex: F
Vaccine: HPV4
Symptoms: Immediate post-injection reaction, Lymphadenopathy, Pharyngolaryngeal pain
Clinical narrative: This is in follow-up to report(s) previously submitted on 7/15/2008. Information has been received from a nurse practitioner concerning a 20 year old female, weight 115lb, with no relevant medical history or allergies who on 07-APR-2008 was vaccinated with a first dose of GARDASIL vaccine by intramuscular injection (lot number 659964/1978U) in deltoid. There was no concomitant medication. About one hour post vaccination, the patient developed swollen neck glands and a sore throat. The patient sought medical attention with a telephone call. The symptoms lasted for 3-4 days and then self resolved. Additional information is not expected.
Age: 16.0
Sex: F
Vaccine: HPV4
Symptoms: Injection site rash, Oxygen saturation normal
Clinical narrative: Information has been received from a registered nurse (RN) concerning a female who was vaccinated with a second dose of GARDASIL vaccine (yeast). There was no concomitant medication. A "few" days later, the patient experienced rash and pain in the injection site arm. At the time of report, no outcomes were reported. Additional information has been requested. This is in follow-up to report(s) previously submitted on 7/15/2008.  Follow up information was received which indicated that the patient was 16 years old and had no pre-existing physician-diagnosed allergies, birth defects, medical conditions.  On 16-JUN-2008 at 3 pm, the patient was vaccinated with a second (also reported as third) dose of GARDASIL (lot #660553/0070X) in right deltoid.  Concomitant therapy included MOTRIN.  There was no illness at time of vaccination.  On 23-JUN-2008.  The patient experienced pain in right arm, right side chest pain and pain when deep inspiratory cough.  The patient was seen in the office.  Chest, right humerus and right shoulder X-Ray were performed and the results were negative.  Another laboratory test indicated that the patient's pulse OX 95% on room air.  At the time of the report, the events persisted.   Additional information has been requested.
Age: 21.0
Sex: F
Vaccine: HPV4
Symptoms: Injection site discolouration, Injection site induration, Injection site pain, Vomiting
Clinical narrative: Information has been received from a nurse practitioner concerning a 20 year old female with hypertension and no allergies who on 08-APR-2008 was vaccinated with a first dose of GARDASIL vaccine (yeast) (lot number 659182/1757U) without incidence (injection site and route not reported).  On 11-JUN-2008 the patient was vaccinated with a second dose of GARDASIL vaccine (yeast) (lot number 660391/0063X) 0.5 ml intramuscularly in the left arm. Concomitant therapy included vitamins (unspecified), citalopram hydrobromide (CELEXA) and lisinopril (manufacturer unknown). A week later the patient vomited once (but also mentioned that it was hot at her work and the air conditioner was not working). The patient also complained of a hard sore area at the injection site. The reporter mentioned that the area was about the size of a dime and dark purple in color. "It looks like a bruise." There was no fever, rash or redness noted at the site. Unspecified medical attention was sought. At the time of reporting, the patient was recovering from all the symptoms. Additional information has been requested. This is in follow-up to report(s) previously submitted on 7/15/2008.  Follow-up information was received from a registered nurse which reported that the patient returned to the office on 27-JUN-2008 for check of her arm.  There were lump and some dislocation where vaccine was given.  The patient was given TYLENOL and IBUPROFEN as needed.  The patient was recovered from all the events.  Additional information is not expected.
Sex: F
Vaccine: HPV4
Symptoms: Cervical dysplasia, Human papilloma virus test positive, Smear cervix abnormal
Clinical narrative: Information has been received regarding a case in litigation. A consumer with hypothyroidism reported that she in September 2007, was vaccinated with a first dose of GARDASIL vaccine (lot number, injection site and route not reported). In December 2007, the patient was vaccinated with a second dose of GARDASIL vaccine (lot number, injection site and route not reported). In March 2008, the patient was vaccinated with a third dose of GARDASIL vaccine 0.5 mL by intramuscular injection (lot number and injection site not reported). Concomitant therapy included NUVARING and levothyroxine. The patient reported she had a normal PAP smear prior to the vaccination. In the beginning of June 2008, the patient had a positive HPV test with squamous dysplasia. The test included HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. The patient sought unspecified medical attention. The patient's events persisted. This is case 1 of 2. Additional information has been requested.
Age: 28.0
Sex: M
Vaccine: PPV
Symptoms: Injection site cellulitis, Injection site erythema, Injection site pain, Injection site swelling, Nuclear magnetic resonance imaging
Clinical narrative: Information has been received from a registered nurse concerning a 28 year old male patient with dysthymic disorder, reactive airways disease and osteoporosis and a history of hypotension, hypercholesterolaemia, tracheostomy and congenital trachimylasia who on 09-OCT-2007 at 14:00, was vaccinated IM into the left deltoid with a first 0.5ml dose of pneumococcal 23v polysaccharide vaccine (lot# 658555/0964U). Concomitant therapy included amlodipine besylate (AMLODIPIN), diclofenac Na (VOLTAREN), hydrocodone bitartrate, gabapentin (NEURONTIN), simvastatin, montelukast sodium (SINGULAIR) and tizanidine hydrochloride. On 11-OCT-2007 2 days after receiving the vaccine, the patient experienced painful swelling and redness at the injection site of the left deltoid muscle reported to last about 3 days. On 12-OCT-2007, the patient was examined in the office and the exam revealed a 3 inch x 5 inch area of redness and swelling at the injection site. The physician diagnosed the area as possibly cellulitis and prescribed levofloxacine (LEVAQUIN), acetaminophen (+) hydrocodone bitartrate (LORTAB) and NSAIDs. An MRI of the left humerous was ordered to rule out abscess. On 15-OCT-2007, the patient recovered. No product quality complaint was involved. Additional information is not expected.
Age: 37.0
Sex: M
Vaccine: HEP, MEN, TD, YF
Symptoms: CSF protein increased, CSF white blood cell count negative, Dizziness, Dysarthria, Guillain-Barre syndrome
Clinical narrative: Initial report received on 23 October 2007 from a literature citation.  These events correspond to case number 8 in the VAERS report # 120262, which a copy was received the same day.  A thirty-seven-year-old male patient, who was an active member of the military, and who had past medical history of hypertension and penicillin allergy, had received a first dose of YF-VAX (lot number 0924020);a third dose of Meningococcal vaccine; a second dose of Hepatitis B vaccine; and a third dose of Td vaccine on 21 April 1998.  The trade names, manufacturer names, lot numbers, routes and sites of administration were not reported.  Sixteen days post-vaccination (07/May 1998), the patient experienced headache, dizziness, blurred vision, and paresthesia of the toes.  Twelve days later (18 May), the patient's symptoms progressed to include slurred speech, lower extremity weakness and incontinence.  The patient was hospitalized (date not reported) and was diagnosed with Guillain Barre syndrome by the treating physician (The yellow fever working group case classification was suspect for Guillain Barre syndrome) and was treated with plasmaphoresis and physical therapy.  A CSF YF IgM was not done, peak CSF protein was 239 mg/dl, and peak WBC was 1 (cell/mm3).  At the time of discharge from the hospital the patient was able to walk independently and was regaining his strength.  The patient's recovery was complex but subsequently recovered.  A corrective version was created on 27 October 2007 with the same latest received date as the previous version of 23 October 2007 for the sole purpose of amending the literature screen to reflect the name of the journal as the citation of the article.  No new relevant medically significant information was added to the case.  A corrective version was created on 28 March 2008 with the same latest received date as the previous version of 23 October 2007 for the sole purpose of amending the product name in the structure field to generic Diphtheria Tetanus Toxoid vaccine (manufacturer unknown), as it was entered incorrectly as T5d2 Adsorbed (manufacturer unknown).  The product was reported correctly in the above narrative.  Primary reporter was amended to literature in the reporter source structure field.  No other relevant medically significant information was received.  This version does not meet reporting criteria to the health authorities.
Age: 37.0
Sex: M
Vaccine: HEP, MEN, TD, YF
Symptoms: Headache, Incontinence, Muscular weakness, Paraesthesia, Physiotherapy
Clinical narrative: Initial report received on 23 October 2007 from a literature citation.  These events correspond to case number 8 in the VAERS report # 120262, which a copy was received the same day.  A thirty-seven-year-old male patient, who was an active member of the military, and who had past medical history of hypertension and penicillin allergy, had received a first dose of YF-VAX (lot number 0924020);a third dose of Meningococcal vaccine; a second dose of Hepatitis B vaccine; and a third dose of Td vaccine on 21 April 1998.  The trade names, manufacturer names, lot numbers, routes and sites of administration were not reported.  Sixteen days post-vaccination (07/May 1998), the patient experienced headache, dizziness, blurred vision, and paresthesia of the toes.  Twelve days later (18 May), the patient's symptoms progressed to include slurred speech, lower extremity weakness and incontinence.  The patient was hospitalized (date not reported) and was diagnosed with Guillain Barre syndrome by the treating physician (The yellow fever working group case classification was suspect for Guillain Barre syndrome) and was treated with plasmaphoresis and physical therapy.  A CSF YF IgM was not done, peak CSF protein was 239 mg/dl, and peak WBC was 1 (cell/mm3).  At the time of discharge from the hospital the patient was able to walk independently and was regaining his strength.  The patient's recovery was complex but subsequently recovered.  A corrective version was created on 27 October 2007 with the same latest received date as the previous version of 23 October 2007 for the sole purpose of amending the literature screen to reflect the name of the journal as the citation of the article.  No new relevant medically significant information was added to the case.  A corrective version was created on 28 March 2008 with the same latest received date as the previous version of 23 October 2007 for the sole purpose of amending the product name in the structure field to generic Diphtheria Tetanus Toxoid vaccine (manufacturer unknown), as it was entered incorrectly as T5d2 Adsorbed (manufacturer unknown).  The product was reported correctly in the above narrative.  Primary reporter was amended to literature in the reporter source structure field.  No other relevant medically significant information was received.  This version does not meet reporting criteria to the health authorities.
Age: 37.0
Sex: M
Vaccine: HEP, MEN, TD, YF
Symptoms: Plasmapheresis, Vision blurred
Clinical narrative: Initial report received on 23 October 2007 from a literature citation.  These events correspond to case number 8 in the VAERS report # 120262, which a copy was received the same day.  A thirty-seven-year-old male patient, who was an active member of the military, and who had past medical history of hypertension and penicillin allergy, had received a first dose of YF-VAX (lot number 0924020);a third dose of Meningococcal vaccine; a second dose of Hepatitis B vaccine; and a third dose of Td vaccine on 21 April 1998.  The trade names, manufacturer names, lot numbers, routes and sites of administration were not reported.  Sixteen days post-vaccination (07/May 1998), the patient experienced headache, dizziness, blurred vision, and paresthesia of the toes.  Twelve days later (18 May), the patient's symptoms progressed to include slurred speech, lower extremity weakness and incontinence.  The patient was hospitalized (date not reported) and was diagnosed with Guillain Barre syndrome by the treating physician (The yellow fever working group case classification was suspect for Guillain Barre syndrome) and was treated with plasmaphoresis and physical therapy.  A CSF YF IgM was not done, peak CSF protein was 239 mg/dl, and peak WBC was 1 (cell/mm3).  At the time of discharge from the hospital the patient was able to walk independently and was regaining his strength.  The patient's recovery was complex but subsequently recovered.  A corrective version was created on 27 October 2007 with the same latest received date as the previous version of 23 October 2007 for the sole purpose of amending the literature screen to reflect the name of the journal as the citation of the article.  No new relevant medically significant information was added to the case.  A corrective version was created on 28 March 2008 with the same latest received date as the previous version of 23 October 2007 for the sole purpose of amending the product name in the structure field to generic Diphtheria Tetanus Toxoid vaccine (manufacturer unknown), as it was entered incorrectly as T5d2 Adsorbed (manufacturer unknown).  The product was reported correctly in the above narrative.  Primary reporter was amended to literature in the reporter source structure field.  No other relevant medically significant information was received.  This version does not meet reporting criteria to the health authorities.
Age: 68.0
Sex: F
Vaccine: HEPA, TD, TYP, YF
Symptoms: Blood product transfusion, CSF protein increased, CSF white blood cell count, Guillain-Barre syndrome, Hypoaesthesia
Clinical narrative: Initial report received on 23 October 2007 from a literature citation. The events in this case correspond to article case number 12, VAERS number 162449. A 68-year-old female patient had received an injection of YF-VAX (lot number not reported, route and site of administration not reported) and an injection of Hepatitis A, Typhoid, and Diph-Tet vaccines (manufacturers, lot numbers, routes and sites of administration not reported). On 17 July 2000. On 25 July 2000, eight days post-vaccination, the patient began to experience symptoms associated with Guillain Barre Syndrome. Symptoms included pains and weakness in her thighs and calves and tingling and numbness in her hands and feet; the day regimen of IVIG and a five day regimen of Plasma-phoresis. CSF YF IgM was not done. Peak CSF WBC was 2, and peak CSK protein was 73 mg/dl. At discharge, it was reported that the patient "did better with feeding, but little improvement in legs. Transferred to intermediate care facility. The patient had clinically improved but had mild neurological residua". The diagnosis from the treating physician was Guillain Barre Syndrome. 29/Oct/2007: Corrective version was created for the purpose of amending the following information. The literature screen journal title was amended with a publication date of //2007 and the reporters name was amended on the vaccine details screen. New information for this version includes the duration of hospitalization which was reported as 19 days. The laboratory test reported in the narrative as "peak CSK protein" is representative of "peak CSF protein".
Age: 68.0
Sex: F
Vaccine: HEPA, TD, TYP, YF
Symptoms: Muscular weakness, Pain in extremity, Paraesthesia, Plasmapheresis
Clinical narrative: Initial report received on 23 October 2007 from a literature citation. The events in this case correspond to article case number 12, VAERS number 162449. A 68-year-old female patient had received an injection of YF-VAX (lot number not reported, route and site of administration not reported) and an injection of Hepatitis A, Typhoid, and Diph-Tet vaccines (manufacturers, lot numbers, routes and sites of administration not reported). On 17 July 2000. On 25 July 2000, eight days post-vaccination, the patient began to experience symptoms associated with Guillain Barre Syndrome. Symptoms included pains and weakness in her thighs and calves and tingling and numbness in her hands and feet; the day regimen of IVIG and a five day regimen of Plasma-phoresis. CSF YF IgM was not done. Peak CSF WBC was 2, and peak CSK protein was 73 mg/dl. At discharge, it was reported that the patient "did better with feeding, but little improvement in legs. Transferred to intermediate care facility. The patient had clinically improved but had mild neurological residua". The diagnosis from the treating physician was Guillain Barre Syndrome. 29/Oct/2007: Corrective version was created for the purpose of amending the following information. The literature screen journal title was amended with a publication date of //2007 and the reporters name was amended on the vaccine details screen. New information for this version includes the duration of hospitalization which was reported as 19 days. The laboratory test reported in the narrative as "peak CSK protein" is representative of "peak CSF protein".
Age: 32.0
Sex: M
Vaccine: HEPA, TYP, YF
Symptoms: Asthenia, Dehydration, Diarrhoea, Hallucination, Malaise
Clinical narrative: Initial report received on 17 January 2008 from a line listing that was the result of a VAERS database search, VAERS# 226480.  VAERS reported received date was 09 September 2004.  A 32-year-old male patient had received injections of TYPHIM VI, lot number not provided; YF-VAX, lot number not provided; and HAVRIX, manufacturer GSK, lot number not provided; on an unspecified date.  At an unspecified time post-vaccination, the patient experienced serum sickness, hallucinations, dehydration, rash, pyrexia, asthenia, diarrhea, malaise, nausea, and pruritus.  The patient subsequently recovered from the event.  Additional information was not provided.
Age: 32.0
Sex: M
Vaccine: HEPA, TYP, YF
Symptoms: Nausea, Pruritus, Pyrexia, Rash, Serum sickness
Clinical narrative: Initial report received on 17 January 2008 from a line listing that was the result of a VAERS database search, VAERS# 226480.  VAERS reported received date was 09 September 2004.  A 32-year-old male patient had received injections of TYPHIM VI, lot number not provided; YF-VAX, lot number not provided; and HAVRIX, manufacturer GSK, lot number not provided; on an unspecified date.  At an unspecified time post-vaccination, the patient experienced serum sickness, hallucinations, dehydration, rash, pyrexia, asthenia, diarrhea, malaise, nausea, and pruritus.  The patient subsequently recovered from the event.  Additional information was not provided.
Sex: F
Vaccine: YF
Symptoms: Headache, Pyrexia
Clinical narrative: Initial report received on 07 September 2007 from the Centers for Disease Control and Prevention as noted in the agenda dated 10 September 2007.  A female patient, (age not specified), had received an injection of YF-VAX, lot number not reported, route and site of administration not reported, in approximately April 2007.  On an unspecified date post-vaccination, the patient experienced fever and a severe headache which required hospitalization.  The patient was being followed by the network.  Recovery status was not reported.  The initial reporter in this case was the same as in case 2007-03069.
Age: 52.0
Sex: F
Vaccine: HEPA, MMR, TDAP, YF
Symptoms: Computerised tomogram normal, Headache, Myalgia, Photophobia
Clinical narrative: Initial report received on 07 September 2007 from the Centers for Disease Control and Prevention as noted in the Yellow Fever Working Group Meeting Agenda dated 10 September 2007, VAERS# 279575. A 52-year-old female patient, had received an injection of YF Vax, lot number not reported; an injection of Tetanus, Diphtheria, and acellular Pertussis vaccine, manufacturer not reported, lot number not reported; an injection of Measles, Mumps, Rubella, and Varicella vaccine (MMRV), manufacturer Merck, lot number not reported; and an injection of Hepatitis A vaccine, manufacturer not reported, lot number not reported; on 13 March 2007. Routes and sites of administration were not reported. Eight days post-vaccination, the patient developed a headache which worsened overnight. She described the headache as the most excruciating headache she had ever had. She also experienced associated generalized myalgia and photophobia. She denied fever. Four days after the onset of the headache, she called a physician and was evaluated. CT scan of the head was normal. The patient was being followed by the Clinical Immunization Safety Assessment Network (CISA). The patient recovered and did not follow-up with the neurologist as planned. The initial reporter in this case was the same as in case 2007-03070.
Age: 36.0
Sex: F
Vaccine: YF
Symptoms: Axillary pain, Dizziness, Headache, Injected limb mobility decreased, Injection site erythema
Clinical narrative: Initial report received from a nurse in the USA on 11 July 2007. A 36 year old, female patient developed a 2 inch, red, swollen, painful area at the injection site on the same day after she received YP-VAX (lot number UF102AA) subcutaneously in the left upper arm on 07 July 2007. Several hours later, she developed significant pain from the injection site to axilla - pain level 7-8 on 0-10 scale. She was unable to use her arm due to pain. She also had significant dizziness and headache that started the evening of 07 July 2007. She was advised to take Advil for the discomfort - it did help. The dizziness did not get better until 10 July 2007. She was examined by the physician on 11 July 2007. She was not allergic to eggs, chicken or gelatin. This was the patient's first yellow fever shot. The patient did not have any illness and she was not on any medication at the time of the vaccination. It was reported the patient recovered. This case is the mother of the family - other family members are detailed in cases 2007-02532 (son's case) and 2007-02534 (daughter's case).
Age: 36.0
Sex: F
Vaccine: YF
Symptoms: Injection site pain, Injection site swelling, Pain in extremity
Clinical narrative: Initial report received from a nurse in the USA on 11 July 2007. A 36 year old, female patient developed a 2 inch, red, swollen, painful area at the injection site on the same day after she received YP-VAX (lot number UF102AA) subcutaneously in the left upper arm on 07 July 2007. Several hours later, she developed significant pain from the injection site to axilla - pain level 7-8 on 0-10 scale. She was unable to use her arm due to pain. She also had significant dizziness and headache that started the evening of 07 July 2007. She was advised to take Advil for the discomfort - it did help. The dizziness did not get better until 10 July 2007. She was examined by the physician on 11 July 2007. She was not allergic to eggs, chicken or gelatin. This was the patient's first yellow fever shot. The patient did not have any illness and she was not on any medication at the time of the vaccination. It was reported the patient recovered. This case is the mother of the family - other family members are detailed in cases 2007-02532 (son's case) and 2007-02534 (daughter's case).
Age: 62.0
Sex: F
Vaccine: YF
Symptoms: Erythema, Pruritus generalised, Rash papular
Clinical narrative: Initial report received from a health care professional in the USA on 11 July 2007. A 62 year old, female patient developed a reddened, raised area on one side of her face, 40 minutes after she received YP-VAX (lot number UF102AA) subcutaneously in the left upper arm on 05 July 2007. The red area faded within 24 hours but the patient had itching all over her body for 48 hours. The patient was not allergic to eggs, chicken or gelatin. She was on baby ASA QD and did not have any illness at the time of vaccination. The symptoms resolved with medical intervention - the patient recovered. Follow-up correspondence received from a health care professional on 14 August 2007. Per the reporter, they have "further information to add". Additional information was not provided. This case is the wife of the patient detailed in case 2007-02531.
Sex: F
Vaccine: HPV4
Symptoms: Convulsion, Fear of death, Loss of consciousness
Clinical narrative: Information has been received from the news media which reported that a female patient who on an unknown date was vaccinated with GARDASIL.  The patient passed out and had a seizure after vaccination with GARDASIL.  After the patient's seizure, she did not want to go to bed because she thought that she wasn't going to be able to wake up.  Upon internal review, the patient's seizure was considered an other important medical event.  No additional information is expected.
Age: 22.0
Sex: F
Vaccine: HEP, HEPA, IPV, TYP, YF, HEP, HEPA, IPV, TYP, YF
Symptoms: Chills, Dizziness, Nausea, Pyrexia
Clinical narrative: Initial report received on 04 September 2007 from a health care professional. A 22-year-old female patient, with no illness at the time of vaccination, had received a "primary series" dose, right upper arm, subcutaneous injection of IPOL, lot number Z0547; a first dose, left upper arm, subcutaneous injection of YF-VAX, lot number UF102AA; a first dose, oral administration of Typhoid vaccine, manufacturer Berna, lot number 3001188; a first dose, right deltoid, intramuscular injection of Hepatitis A vaccine, manufacturer GSK, lot number AHAVB115CA; and a fourth dose, left deltoid, intramuscular injection of Hepatitis B vaccine, manufacturer GSK, lot number AHBVB359AA, on 29 August 2007. The next day, the patient became dizzy, nauseated, had chills, and had fever up to 103.2 degrees Fahrenheit. The patient spoke with a physician via phone and was advised to treat with Tylenol. Relevant diagnostic testing was none. The patient recovered from the event. Follow-up information was received on 05 November 2007. The reporter confirmed that the reported event did not require an examination by a physician. The reporter also verified that the first dose of oral typhoid had been administered at home at 10:30PM (22:30). Additional information was provided relevant to the patients medical history and ongoing illness status at the time of vaccination. The patient had developed an inflammation of her lower eyelid on 02 August 2007, 27 days prior to vaccination, and went to the emergency department (ED) where the condition was thought to be ocular herpes or a viral conjunctivitis. The following day, the patient had blurred vision so they returned to the ED and the ophthalmologist on call stated "it did not look like herpes". The patient then followed up 09 September 2007 with another ophthalmologist who felt the condition was herpes. The patient then visited her general physician "over the weekend" (date not specified) who stated the condition was some type of viral illness and was prescribed acyclovir. No further information was provided.
Age: 50.0
Sex: M
Vaccine: HEPAB, IPV, PPV, TDAP, TYP, YF, HEPAB, IPV, PPV, TDAP, TYP, YF
Symptoms: Pancreatitis
Clinical narrative: Initial report received on 07 March 2008 from the Centers of Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304893. A 50-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, IPOL, TDAP, PNEUMOCOCCAL VACCINE, and TWINRIX; on 22 January 2008. Seventeen days post-vaccination, the patient developed pancreatitis, which required hospitalization. The patient's serum was sent for unspecified testing and had not been completed at the time of this report. The patient recovered from the event. Additional information was not provided.
Age: 50.0
Sex: M
Vaccine: HEPAB, IPV, PPV, TDAP, TYP, YF, HEPAB, IPV, PPV, TDAP, TYP, YF
Symptoms: Pancreatitis, Serology test
Clinical narrative: Initial report received on 07 March 2008 from the Centers of Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304893. A 50-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, IPOL, TDAP, PNEUMOCOCCAL VACCINE, and TWINRIX; on 22 January 2008. Seventeen days post-vaccination, the patient developed pancreatitis, which required hospitalization. The patient's serum was sent for unspecified testing and had not been completed at the time of this report. The patient recovered from the event. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Blood immunoglobulin M, CSF lymphocyte count increased, CSF protein increased, Constipation, Encephalitis
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Extensor plantar response, Foreign travel, Hyperreflexia, Hypoaesthesia, Lumbar puncture abnormal
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Muscular weakness, Nuclear magnetic resonance imaging abnormal, Nuclear magnetic resonance imaging brain abnormal, Pleocytosis, Pyrexia
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Rash, Upper motor neurone lesion, Urinary retention
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Blood immunoglobulin G normal, Blood immunoglobulin M increased, CSF cell count normal, Encephalitis, Pyrexia
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Rash
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Arthropod bite, Asthenia, Ataxia, CSF protein increased, CSF test abnormal
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: CSF white blood cell count increased, Chills, Computerised tomogram abnormal, Faecaloma, Headache
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Hyperaesthesia, Hypoaesthesia, Leukoencephalomyelitis, Nausea, Nuclear magnetic resonance imaging abnormal
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.
Age: 23.0
Sex: M
Vaccine: DT, TYP, YF, TD, TYP, YF, TD, TYP, YF
Symptoms: Nuclear magnetic resonance imaging brain normal, Pyrexia, Rash, Urinary retention, Vomiting
Clinical narrative: Initial report received on 07 March 2008 from the Centers for Disease Control and Prevention's Yellow Fever Working Group, VAERS# 304960. A 23-year-old male patient had received an injection of YF-VAX (first dose), TYPHIM VI, and DIPHTHERIA and TETANUS TOXOID vaccine, manufacturer not reported; on 19 December 2007. Lot numbers were not reported. At an unknown interval post-vaccination, the patient developed a fever (temperature not specified) and a rash. He then took a trip. On 01 February 2008, the patient was hospitalized for six days for encephalomyelitis. He was treated with intravenous steroids and "improved." Serum IgM was positive and IgG was negative. Cerebrospinal fluid was IgM positive. Additional information was not provided.